Recent blog posts
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
Hot Spotlight
7 min read
Boehringer Ingelheim: Continuously Investing in the Development of Schizophrenia Treatment Drugs Targeting GPR52
19 March 2024
On March 11th, Boehringer Ingelheim partnered with Sosei Group in an exclusive deal to create and market a novel schizophrenia drug, a GPR52 agonist.
Read →
Several bispecific antibodies targeting GPCRs
Hot Spotlight
5 min read
Several bispecific antibodies targeting GPCRs
15 March 2024
Bispecific antibodies (bsAbs) possess unique advantages due to their ability to simultaneously target two distinct antigens, which helps to enhance the immune system's recognition and killing of tumor cells.
Read →
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
Hot Spotlight
7 min read
Tegileridine vs Oliceridine: Comparison of New Analgesic Drugs Targeting Opioid Receptors
15 March 2024
In January, Jiangsu Hengrui Pharmaceuticals' Tegileridine Fumarate injection, for treating moderate to severe post-op abdominal pain, was approved in China.
Read →
Latest Advances and Applications of Bispecific Antibodies in Cancer Treatment
Hot Spotlight
15 min read
Latest Advances and Applications of Bispecific Antibodies in Cancer Treatment
12 March 2024
On March 6th, Nature Reviews Drug Discovery highlighted recent bispecific antibodies (bsAbs) progress in cancer therapy.
Read →
Progress on Amgen's Weight Loss Pipeline: AMG 133
Hot Spotlight
10 min read
Progress on Amgen's Weight Loss Pipeline: AMG 133
12 March 2024
In February, Amgen published a study in Nature Metabolism about AMG 133, a novel molecule with potential for treating obesity.
Read →
Tharimmune's Oral Mucosal Film Medication TH104 Targeting Opioid Receptors
Hot Spotlight
4 min read
Tharimmune's Oral Mucosal Film Medication TH104 Targeting Opioid Receptors
12 March 2024
Tharimmune revealed on their website plans to start a Phase 1 trial for TH104, assessing safety and bioavailability, with early results due Q2 2024.
Read →
Advancements in Clinical Research and Development of Obesity Treatment Medications
Hot Spotlight
21 min read
Advancements in Clinical Research and Development of Obesity Treatment Medications
7 March 2024
In February, University of Leicester and Leicester Diabetes Centre experts published a summary of obesity treatments in "International Journal of Obesity," highlighting new drugs inspired by gut incretin hormones.
Read →
Progress in the Discovery of New Drugs Targeting GPCR Class for Gastric Cancer
Hot Spotlight
14 min read
Progress in the Discovery of New Drugs Targeting GPCR Class for Gastric Cancer
1 March 2024
Gastric Cancer (GC) is a deadly global malignancy with over 1 million new cases in 2022, resulting in 783,000 deaths.
Read →
Development Trends of Peptide Pharmaceuticals
Hot Spotlight
17 min read
Development Trends of Peptide Pharmaceuticals
1 March 2024
This article provides an interpretation of a review published in the 2021 issue of "Nature Reviews Drug Discovery", which analyzes the history and trends of peptide drug development over the past 100 years.
Read →
Clinical Dose and Translational Science of the JAK1 Inhibitor Upadacitinib
Hot Spotlight
11 min read
Clinical Dose and Translational Science of the JAK1 Inhibitor Upadacitinib
27 February 2024
Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.
Read →
Progress in the Research and Development of Cannabinoid Receptor New Drugs
Hot Spotlight
12 min read
Progress in the Research and Development of Cannabinoid Receptor New Drugs
27 December 2023
Cannabinoids can be categorized into three types based on their origin: endocannabinoids, phytocannabinoids, and synthetic cannabinoids.
Read →
ADC drugs worth paying attention to in Clinical Phase III/II/I
Hot Spotlight
10 min read
ADC drugs worth paying attention to in Clinical Phase III/II/I
17 November 2023
Apart from the approved ADCs, there are hundreds of ADCs under clinical investigation, covering a increasingly diverse range of targets.
Read →